The Directors of Solagran Limited are pleased to advise the market of a shareholder information evening to be held at 6.00pm on 3 September at the Parkview Hotel in Melbourne at which shareholders will be given an update in relation to a number of important technological and strategic developments within the company.
In addition to presentations from Solagran Executive Directors, the information evening will include presentations from three visitors from Russia: Mr Alexander Kurganov, Managing Director of SibEX; Dr Tamara Nikitina, Solagran’s Clinical Trials Co-ordinator; and Ms Marina Orlova, an award winning documentary producer who has been working for more than a year on a documentary about Solagran and Bioeffectives® for Russian television.
The Executive Directors will provide a briefing on both strategy and operations and in so doing, will demonstrate the commercial significance of having a substantial investment in the world’s first and only commercial scale plant capable of producing pharmaceutical grade polyprenols (Bioeffective® R) using patent protected technology.
The Executive Chairman will provide a briefing on marketing activities in relation to Ropren® in Russia, and report on the high level of interest in both Ropren® and Bioeffective® A emerging from his participation in a recent infectious diseases conference convened by the Pasteur Institute.
Mr Kurganov will provide a detailed presentation in relation to the Tomsk production facility as well as the company’s plans for the construction of a much larger facility within the Tomsk special economic zone.
Dr Nikitina has been working with Bioeffectives® since the mid 1970s. She will provide an overview of Solagran’s ongoing clinical trials program and comment on the results of some recent trials.
Ms Orlova will speak to shareholders about what she has learned in relation to both Solagran and its Bioeffectives® research program during an extensive period of preproduction research, followed by more than 6 months filming in Russia. She and her film crew are in Australia to conduct interviews and to capture the footage they require for the Australian component of the documentary. It is also planned that they travel to Dubai to cover the Equine Gastric Ulcer Syndrome (EGUS) trials being undertaken in conjunction with Solagran’s strategic partner BioProspect Limited.
All presenters will be available to answer shareholder questions.
Peter Stedwell Executive Director On behalf of the Board of Directors Solagran Limited
SLA Price at posting:
0.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)